Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Shun Xin Wang‐Lin"'
1
Akademický článek
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab
Autor: Marie‐Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 7, Pp 1117-1129 (2024)
Abstract Cytokine release syndrome (CRS) was associated with teclistamab treatment in the phase I/II MajesTEC‐1 study. Cytokines, especially interleukin (IL)‐6, are known suppressors of cytochrome P450 (CYP) enzymes' activity. A physiologically b
Externí odkaz: https://doaj.org/article/0dd1551fb54644b2acd2b604cad8206a
Zobrazit plný text záznamu
2
Akademický článek
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
Autor: Shun Xin Wang-Lin, Joseph P. Balthasar
Publikováno v: Antibodies, Vol 7, Iss 1, p 5 (2018)
Antibiotic-resistant bacterial pathogens are increasingly implicated in hospital- and community-acquired infections. Recent advances in monoclonal antibody (mAb) production and engineering have led to renewed interest in the development of antibody-b
Externí odkaz: https://doaj.org/article/f817213ea44c472d9cbdd995c0e53e32
Zobrazit plný text záznamu
3
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
Autor: Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi W. Hilder, Jeffery Russell, Jeffrey Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg
Publikováno v: Blood Advances. 7:644-648
B-cell maturation antigen (BCMA) is selectively expressed as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of patients with MM. The bispecific antibodies
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727f72e5fbe7d8308419bbb499db885f
https://doi.org/10.1182/bloodadvances.2022007625
Zobrazit plný text záznamu
5
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Autor: Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C Adams, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed
Publikováno v: Targeted Oncology. 17:433-439
Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evalua
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f9766eaeac3d6c36a98101ebf36d06
https://doi.org/10.1007/s11523-022-00893-y
Zobrazit plný text záznamu
6
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
Autor: Zhenhua Xu, Jocelyn H. Leu, Yan Xu, Ivo Nnane, Sophia G. Liva, Shun Xin Wang‐Lin, Rachel Kudgus‐Lokken, An Vermeulen, Daniele Ouellet
Publikováno v: Clinical pharmacology and therapeutics.
Therapeutic proteins may first be developed as intravenous (IV) therapies with new subcutaneous (SC) dosage forms being subsequently developed to provide an alternative route of administration. As of August 2022, there have been 9 therapeutic protein
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acd5888688ce43ac7232bb6cc125a0e2
https://pubmed.ncbi.nlm.nih.gov/36516352
Zobrazit plný text záznamu
9
Antibody Dependent Enhancement ofAcinetobacter baumanniiInfection in a Mouse Pneumonia Model
Autor: Ruth Olson, Janet M. Beanan, Shun Xin Wang-Lin, Thomas A. Russo, Joseph P. Balthasar, Ulrike MacDonald
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 368:475-489
Acinetobacter baumannii has become a pathogen of increasing medical importance because of the emergence of multidrug-resistant strains and the high rate of mortality of infected patients. Promising animal study results have been reported recently wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::956d27ea6483c62a2c6c6ba4717c89fa
https://doi.org/10.1124/jpet.118.253617
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje